Submitted:
22 October 2024
Posted:
24 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Method Optimization and Validation
2.2. Nitazenes Stability
3. Discussion
4. Materials and Methods
4.1. Chemicals and Reagents
4.2. Calibrators and Quality Control (QC) Samples
4.3. Stability Study Design
4.4. Sample Preparation
4.5. Instrumental Analysis
4.6. Method Validation
4.6.1. Linearity
4.6.2. Bias
4.6.3. Precision
4.6.4. Sensitivity
4.6.6. Carryover
4.6.7. Recovery and Matrix Effect
4.7. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ujváry, I.; Christie, R.; Evans-Brown, M.; Gallegos, A.; Jorge, R.; De Morais, J.; Sedefov, R. DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles. ACS Chem. Neurosci. 2021, 12, 1072–1092. [Google Scholar] [CrossRef] [PubMed]
- National Center for Health Statistics U.S. Overdose Deaths Decrease in 2023, First Time Since 2018 Available online: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm.
- Di Trana, A.; Pichini, S.; Pacifici, R.; Giorgetti, R.; Busardò, F.P. Synthetic Benzimidazole Opioids: The Emerging Health Challenge for European Drug Users. Front. Psychiatry 2022, 13, 858234. [Google Scholar] [CrossRef] [PubMed]
- Schüller, M.; Lucic, I.; Øiestad, Å.M.L.; Pedersen-Bjergaard, S.; Øiestad, E.L. High-Throughput Quantification of Emerging “Nitazene” Benzimidazole Opioid Analogs by Microextraction and UHPLC–MS-MS. Journal of Analytical Toxicology 2023, 47, 787–796. [Google Scholar] [CrossRef] [PubMed]
- European Monitoring Centre for Drugs and Drug Addiction Isotonitazene. Report on the Risk Assessment of N,N-Diethyl-2- [[4-(1-Methylethoxy)Phenyl]Methyl]-5-Nitro-1Hbenzimidazole- 1-Ethanamine (Isotonitazene) in Accordance with Article 5c of Regulation (EC) No 1920/2006 (as Amended);
- Schumann, J.L.; Syrjanen, R.; Alford, K.; Mashetty, S.; Castle, J.W.; Rotella, J.; Maplesden, J.; Greene, S.L. Intoxications in an Australian Emergency Department Involving ‘Nitazene’ Benzylbenzimidazole Synthetic Opioids (Etodesnitazene, Butonitazene and Protonitazene). Journal of Analytical Toxicology 2023, 47, e6–e9. [Google Scholar] [CrossRef] [PubMed]
- Di Trana, A.; La Maida, N.; Froldi, R.; Scendoni, R.; Busardò, F.P.; Pichini, S. The New Synthetic Benzimidazole Opioid Etonitazepipne: An Emerging Fatal Harm and a Challenge for Laboratory Medicine. Clinical Chemistry and Laboratory Medicine (CCLM) 2023, 61, e200–e202. [Google Scholar] [CrossRef] [PubMed]
- United Nations Office on Drugs and Crime SPECIAL POINTS OF INTEREST. In The World Drug Report 2024.
- Walton, S.E.; Krotulski, A.J.; Logan, B.K. A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography–Tandem Quadrupole Mass Spectrometry (LC–QQQ-MS). Journal of Analytical Toxicology 2022, 46, 221–231. [Google Scholar] [CrossRef] [PubMed]
- Ververi, C.; Galletto, M.; Massano, M.; Alladio, E.; Vincenti, M.; Salomone, A. Method Development for the Quantification of Nine Nitazene Analogs and Brorphine in Dried Blood Spots Utilizing Liquid Chromatography – Tandem Mass Spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2024, 241, 115975. [Google Scholar] [CrossRef] [PubMed]
- Andrlova, L.; Kandar, R. The Dried Blood Spot Sampling Method in the Laboratory Medicine. BLL 2019, 120, 223–234. [Google Scholar] [CrossRef] [PubMed]
- Palmquist, K.B.; Truver, M.T.; Shoff, E.N.; Krotulski, A.J.; Swortwood, M.J. Review of Analytical Methods for Screening and Quantification of Fentanyl Analogs and Novel Synthetic Opioids in Biological Specimens. Journal of Forensic Sciences 2023, 68, 1643–1661. [Google Scholar] [CrossRef] [PubMed]
- Academy Standards Board; American Academy of Forensic Sciences Standard Practices for Method Validation in Forensic Toxicology Available online: https://www.aafs.org/academy-standards-board.
- Van Loco, J.; Elskens, M.; Croux, C.; Beernaert, H. Linearity of Calibration Curves: Use and Misuse of the Correlation Coefficient. Accreditation and Quality Assurance 2002, 7, 281–285. [Google Scholar] [CrossRef]
- Müller, I.R.; Linden, G.; Charão, M.F.; Antunes, M.V.; Linden, R. Dried Blood Spot Sampling for Therapeutic Drug Monitoring: Challenges and Opportunities. Expert Review of Clinical Pharmacology 2023, 16, 691–701. [Google Scholar] [CrossRef] [PubMed]
- Abu-Rabie, P.; Denniff, P.; Spooner, N.; Chowdhry, B.Z.; Pullen, F.S. Investigation of Different Approaches to Incorporating Internal Standard in DBS Quantitative Bioanalytical Workflows and Their Effect on Nullifying Hematocrit-Based Assay Bias. Anal. Chem. 2015, 87, 4996–5003. [Google Scholar] [CrossRef] [PubMed]
- Mommers, J.; Mengerink, Y.; Ritzen, E.; Weusten, J.; Van Der Heijden, J.; Van Der Wal, S. Quantitative Analysis of Morphine in Dried Blood Spots by Using Morphine-D3 Pre-Impregnated Dried Blood Spot Cards. Analytica Chimica Acta 2013, 774, 26–32. [Google Scholar] [CrossRef] [PubMed]
- Capiau, S.; Veenhof, H.; Koster, R.A.; Bergqvist, Y.; Boettcher, M.; Halmingh, O.; Keevil, B.G.; Koch, B.C.P.; Linden, R.; Pistos, C.; et al. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot–Based Methods for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2019, 41, 409–430. [Google Scholar] [CrossRef] [PubMed]
- Timmerman, P.; White, S.; Globig, S.; Lüdtke, S.; Brunet, L.; Smeraglia, J. EBF Recommendation on the Validation of Bioanalytical Methods for Dried Blood Spots. Bioanalysis 2011, 3, 1567–1575. [Google Scholar] [CrossRef] [PubMed]
- Deprez, S.; Stove, C. Application of a Fully Automated Dried Blood Spot Method for Therapeutic Drug Monitoring of Immunosuppressants: Another Step Toward Implementation of Dried Blood Spot Analysis. Archives of Pathology & Laboratory Medicine 2023, 147, 786–796. [Google Scholar] [CrossRef]
- Matuszewski, B.K.; Constanzer, M.L.; Chavez-Eng, C.M. Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS. Anal. Chem. 2003, 75, 3019–3030. [Google Scholar] [CrossRef] [PubMed]






| Analyte | Linear range (ng/mL) |
r2 | LOD (ng/mL) |
LOQ (ng/mL) |
Accuracy (%CV) |
Inter-day precision (%CV) |
Intra-day precision (%CV) |
Recovery (%) |
Matrix Effect (%) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| lQC | mQC | hQC | lQC | mQC | hQC | lQC | mQC | hQC | lQC | mQC | hQC | lQC | mQC | hQC | |||||
| Etazene | 1-20 | 0.995 | 0.25 | 0.5 | 8 | 21 | 11 | 12 | 18 | 4 | 15 | 7 | 13 | 99 | 89 | 84 | 88 | 108 | 97 |
| Flunitazene | 1-20 | 0.997 | 0.25 | 0.5 | 10 | 9 | 8 | 15 | 12 | 9 | 12 | 9 | 18 | 95 | 110 | 105 | 80 | 110 | 95 |
| Isotonitazene | 1-20 | 0.993 | 0.5 | 0.5 | 17 | 20 | 12 | 8 | 16 | 11 | 18 | 11 | 12 | 91 | 117 | 92 | 108 | 93 | 96 |
| Protonitazene | 1-20 | 0.992 | 0.5 | 0.5 | 18 | 15 | 16 | 3 | 5 | 2 | 11 | 12 | 16 | 93 | 92 | 99 | 112 | 108 | 101 |
| Analyte | [M+H]+ m/z | Acquisition window (min) | Retention time (min) |
|---|---|---|---|
| Etazene | 352.2385 | 2.5 - 4.5 | 3.91 |
| Flunitazene | 371.1871 | 3.1 – 5.1 | 4.69 |
| Isotonitazene | 411.2386 | 4.1 – 6.1 | 5.06 |
| Protonitazene | 5.18 | ||
| Fentanyl-d5 | 342.2588 | 4.83 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).